Journal Article

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

Wong, Conroy, Karalus, Noel, Hockey, Hans, Eaton, Tam, Storey, Louanne, Milne, David, Ashton, Toni, Sexton, Paul, Tong, Cecilia, Fergusson, Wendy, Tuffery, Christine, Jayaram, Lata

2012

Overview

Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis. We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defined by high-resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratified by centre. Participants, research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of event-based exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV1) before bronchodilation, and change in total score on St George's respiratory questionnaire (SGRQ). Analyses were by intention to treat. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493. 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations was 0·59 per patient in the azithromycin group and 1·57 per patient in the placebo group in the 6-month treatment period (rate ratio 0·38, 95% CI 0·26–0·54; p<0·0001). Prebronchodilator FEV1 did not change from baseline in the azithromycin group and decreased by 0·04 L in the placebo group, but the difference was not significant (0·04 L, 95% CI −0·03 to 0·12; p=0·251). Additionally, change in SGRQ total score did not differ between the azithromycin (–5·17 units) and placebo groups (–1·92 units; difference −3·25, 95% CI −7·21 to 0·72; p=0·108). Azithromycin is a new option for prevention of exacerbations in patients with non-cystic fibrosis bronchiectasis with a history of at least one exacerbation in the past year. Health Research Council of New Zealand and Auckland District Health Board Charitable Trust.

• Publisher: Elsevier Ltd,Elsevier,Elsevier Limited
• Subject: Adult / Aged / Anti-Bacterial Agents - administration & dosage / Anti-Bacterial Agents - adverse effects / Anti-Bacterial Agents - therapeutic use / Antibiotics / azithromycin / Azithromycin - administration & dosage / Azithromycin - adverse effects / Azithromycin - therapeutic use / Biological and medical sciences / Bronchiectasis - etiology / Bronchiectasis - physiopathology / Bronchiectasis - prevention & control / clinical trials / Cystic Fibrosis - complications / Double-Blind Method / Drug Administration Schedule / Drug therapy / Errors of metabolism / Female / fibrosis / Forced Expiratory Volume - drug effects / General aspects / Humans / immunomodulators / Internal Medicine / lung function / Male / Medical research / Medical sciences / Metabolic diseases / Middle Aged / Miscellaneous hereditary metabolic disorders / Mortality / New Zealand / patients / Prevention / Prevention and actions / Public health. Hygiene / Public health. Hygiene-occupational medicine / Quality of Life / questionnaires / Respiratory function / Secondary Prevention / Streptococcus infections / Treatment Outcome / Vital Capacity - drug effects